# Clinical Cases: Obstructive Lung Diseases

## Case 1: Acute Severe Asthma Exacerbation

### Clinical Image
![COPD and emphysema pathophysiology](case_01_image.jpg)
*Source: [Wikimedia Commons - COPD](https://commons.wikimedia.org/wiki/File:COPD.png) - CC BY-SA 4.0*

### Case Presentation
A 24-year-old woman with a history of asthma presents to the emergency department with severe dyspnea and wheezing that has worsened despite using her albuterol inhaler repeatedly over the past 6 hours. She reports a recent upper respiratory infection. She appears anxious and is unable to speak in full sentences. Vital signs show heart rate 125 bpm, blood pressure 145/90 mmHg, respiratory rate 32/min, and oxygen saturation 88% on room air.

On examination, she is sitting upright, using accessory muscles of respiration, with audible wheezing. Lung auscultation reveals diffuse bilateral expiratory wheezes with prolonged expiratory phase. Peak expiratory flow is 120 L/min (personal best 450 L/min, 27% of personal best). Arterial blood gas on room air shows pH 7.38, PaCO2 42 mmHg, PaO2 58 mmHg.

The normal PaCO2 in this severely dyspneic patient is concerning. In a typical asthma exacerbation, hyperventilation from hypoxemia and dyspnea causes hypocapnia (low PaCO2). A "normal" PaCO2 in the setting of severe respiratory distress indicates respiratory muscle fatigue and impending respiratory failure - the patient can no longer maintain the hyperventilation needed to compensate.

The pathophysiology involves bronchospasm from smooth muscle contraction, mucosal edema, and mucus plugging, all causing severe airway obstruction. The obstructed airways cause air trapping (unable to fully exhale before next inspiration begins), leading to dynamic hyperinflation that further compromises respiratory mechanics.

The patient receives continuous nebulized albuterol, IV magnesium sulfate (smooth muscle relaxant), IV methylprednisolone (reduces inflammation), and supplemental oxygen. She is closely monitored for deterioration requiring intubation. Over 4 hours, her peak flow improves to 280 L/min, PaCO2 decreases to 32 mmHg (indicating improved ventilatory capacity), and she is admitted to a monitored bed. She is discharged 3 days later on inhaled corticosteroids with a rescue inhaler and an asthma action plan.

### Key Learning Points
- In acute asthma, a "normal" PaCO2 is a warning sign of impending respiratory failure
- Peak expiratory flow less than 25% of personal best indicates severe exacerbation
- Dynamic hyperinflation from air trapping increases work of breathing
- Accessory muscle use, inability to speak in sentences, and declining PaCO2 indicate severity
- Treatment includes beta-agonists, corticosteroids, and ipratropium; magnesium sulfate for severe cases

---

## Case 2: COPD Exacerbation with Hypercapnic Respiratory Failure

### Case Presentation
A 68-year-old man with a 60 pack-year smoking history and severe COPD (FEV1 25% predicted) presents with increased dyspnea, cough with purulent sputum, and confusion over 3 days. He is on home oxygen at 2 L/min. On examination, he is somnolent but arousable, with cyanosis and use of accessory muscles. Vital signs show heart rate 110 bpm, blood pressure 155/95 mmHg, respiratory rate 12/min, and oxygen saturation 78% on 2 L/min nasal cannula. Chest examination reveals decreased breath sounds bilaterally, scattered wheezes, and prolonged expiration.

Arterial blood gas on 2 L/min O2 shows pH 7.22, PaCO2 88 mmHg, PaO2 45 mmHg, HCO3 35 mEq/L. Chest X-ray shows hyperinflated lungs without focal consolidation.

The ABG reveals acute-on-chronic hypercapnic respiratory failure. His baseline chronic hypercapnia (suggested by elevated HCO3 of 35) has acutely worsened. The very low respiratory rate of 12/min in a dyspneic patient is ominous - it indicates CO2 narcosis, where severe hypercapnia depresses the CNS including respiratory centers.

The patient is initiated on BiPAP (bilevel positive airway pressure) at IPAP 14 / EPAP 6. This provides inspiratory support to augment tidal volume and reduce work of breathing, while EPAP helps maintain airway patency and recruit atelectatic lung. FiO2 is titrated to maintain SpO2 88-92% - higher targets risk suppressing hypoxic respiratory drive in this chronic CO2 retainer.

Over 2 hours, he becomes more alert, respiratory rate increases to 18/min, and repeat ABG shows pH 7.32, PaCO2 68 mmHg. He is continued on BiPAP overnight with gradual improvement. He receives antibiotics for presumed infectious exacerbation and systemic corticosteroids. He avoids intubation and is discharged after 5 days on optimized inhaler therapy.

### Key Learning Points
- COPD patients with chronic hypercapnia rely partly on hypoxic drive for respiration
- Oxygen targets in COPD exacerbation are SpO2 88-92% to avoid suppressing hypoxic drive
- CO2 narcosis causes CNS depression including paradoxically decreased respiratory rate
- Non-invasive ventilation (BiPAP) reduces intubation rates and mortality in COPD exacerbation
- The FEV1/FVC ratio less than 0.70 defines COPD; FEV1 severity grades disease

---

## Case 3: Bronchiectasis with Pseudomonas Colonization

### Case Presentation
A 45-year-old woman with a history of recurrent pneumonias since childhood presents with chronic productive cough that has worsened over the past month. She produces approximately 50 mL of purulent, foul-smelling sputum daily. She reports intermittent hemoptysis (blood-streaked sputum) and has had three hospitalizations in the past year for respiratory infections requiring IV antibiotics. On examination, she has digital clubbing and scattered crackles over the lower lung fields bilaterally. Vital signs are stable with oxygen saturation 94% on room air.

Sputum culture grows Pseudomonas aeruginosa, the same organism isolated on multiple previous cultures. High-resolution CT chest shows bilateral lower lobe bronchial wall thickening, bronchial dilation (bronchi larger than accompanying pulmonary artery - "signet ring sign"), and lack of bronchial tapering toward the periphery, consistent with bronchiectasis. Pulmonary function tests show FEV1 62% predicted, FVC 78% predicted, FEV1/FVC 0.62, indicating obstructive physiology.

Bronchiectasis is defined as permanent abnormal bronchial dilation from chronic infection and inflammation. A vicious cycle develops: initial airway injury impairs mucociliary clearance, allowing bacterial colonization, which triggers chronic inflammation, causing further airway damage and worsening clearance. Pseudomonas aeruginosa is particularly problematic because it forms biofilms in damaged airways and is difficult to eradicate.

The patient's management includes twice-daily airway clearance therapy with a flutter valve device, nebulized hypertonic saline to improve secretion clearance, chronic suppressive therapy with inhaled tobramycin (alternating months on/off) given her chronic Pseudomonas colonization and frequent exacerbations, and azithromycin three times weekly for its anti-inflammatory and immunomodulatory effects. Her exacerbation frequency decreases from 3-4 per year to 1-2 per year with this regimen.

### Key Learning Points
- Bronchiectasis is permanent bronchial dilation from chronic infection/inflammation
- The "vicious cycle" involves impaired clearance, bacterial colonization, inflammation, and further damage
- Pseudomonas aeruginosa colonization is associated with more rapid decline and frequent exacerbations
- CT findings include "signet ring sign" (dilated bronchus larger than artery) and lack of bronchial tapering
- Management includes airway clearance, mucolytics, and often chronic suppressive antibiotics